[go: up one dir, main page]

PE20181319A1 - Compuestos de isoindol - Google Patents

Compuestos de isoindol

Info

Publication number
PE20181319A1
PE20181319A1 PE2018001126A PE2018001126A PE20181319A1 PE 20181319 A1 PE20181319 A1 PE 20181319A1 PE 2018001126 A PE2018001126 A PE 2018001126A PE 2018001126 A PE2018001126 A PE 2018001126A PE 20181319 A1 PE20181319 A1 PE 20181319A1
Authority
PE
Peru
Prior art keywords
compounds
isoindole
alkyl
hydroxypropan
ethylsulfonyl
Prior art date
Application number
PE2018001126A
Other languages
English (en)
Inventor
Sarah LEVER
Frank Narjes
Roine Ingemar Olsson
Berg Stefan Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20181319A1 publication Critical patent/PE20181319A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a compuestos derivado de isoindol de formula (I), R1 es H o (CO)R4; R2 es alquilo C1-6, ciclopropilo, entre otros; R3 es H, alquilo C1-6, entre otros; R4 es H, alquilo C1-6, entre otros. Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos, sus sales farmaceuticamente aceptables y procesos para prepararlos. Son compuestos preferidos: 5-(etilsulfonil)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)fenil]-2,3-dihidro-1H-isoindol-1-carboxamida, 5-(etilsulfonil)-2-formil-N-[4-(1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)fenil]-2,3-dihidro-1H-isoindol-1-carboxamida, entre otros. Dichos compuestos regulan la actividad del receptor de acido retinoico (ROR) y son utiles para el tratamiento o prevencion de enfermedades tales como psoriasis, espondilitis anquilosante, artritis psoriasica, entre otras
PE2018001126A 2015-12-15 2016-12-14 Compuestos de isoindol PE20181319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562267391P 2015-12-15 2015-12-15

Publications (1)

Publication Number Publication Date
PE20181319A1 true PE20181319A1 (es) 2018-08-14

Family

ID=57708552

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001126A PE20181319A1 (es) 2015-12-15 2016-12-14 Compuestos de isoindol

Country Status (27)

Country Link
US (4) US10011566B2 (es)
EP (1) EP3390396B1 (es)
JP (1) JP6448867B2 (es)
KR (1) KR101947976B1 (es)
CN (1) CN109071516B (es)
AR (1) AR107054A1 (es)
AU (1) AU2016374294B2 (es)
BR (1) BR112018011851A2 (es)
CA (1) CA3007893A1 (es)
CL (1) CL2018001573A1 (es)
CO (1) CO2018005983A2 (es)
CR (1) CR20180328A (es)
DO (1) DOP2018000148A (es)
EA (1) EA034514B1 (es)
ES (1) ES2927631T3 (es)
IL (1) IL259818B (es)
MX (1) MX376029B (es)
MY (1) MY196276A (es)
NI (1) NI201800071A (es)
PE (1) PE20181319A1 (es)
PH (1) PH12018501237A1 (es)
SG (1) SG11201804587QA (es)
SV (1) SV2018005713A (es)
TN (1) TN2018000188A1 (es)
TW (1) TWI728017B (es)
WO (1) WO2017102784A1 (es)
ZA (1) ZA201804618B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804587QA (en) 2015-12-15 2018-06-28 Astrazeneca Ab Isoindole compounds
JP2020524660A (ja) * 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
WO2020035556A1 (en) * 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2020035557A1 (en) * 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2021228217A1 (zh) * 2020-05-15 2021-11-18 上海辉启生物医药科技有限公司 可用作RORγ调节剂的苯胺类化合物
TW202146389A (zh) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 可用作RORγ調節劑的聯芳基類化合物
KR102422891B1 (ko) 2022-01-26 2022-07-20 (주)셀시스템 Ai기반 우선순위 제어기능을 구비한 일체형 태양광 온수 및 배터리 충전장치 및 이를 이용한 충전 방법
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9909242A (pt) 1998-02-25 2000-11-14 Genetics Inst Inibidores de fosfolipase a2
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1212065A4 (en) 1999-07-08 2004-02-11 Tularik Inc COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
US7385063B2 (en) 2001-01-26 2008-06-10 Chugai Seiyaku Kabushiki Kaisha Method for preparing imidazole derivatives
WO2003041641A2 (en) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003082198A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Methods of treatment with lxr modulators
EP1501867A1 (en) 2002-04-29 2005-02-02 Novartis AG Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
US20060189693A1 (en) 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
JP2007500158A (ja) 2003-07-28 2007-01-11 グラクソ　グループ　リミテッド Ｌｘｒアゴニストを用いる炎症性腸疾患の治療方法
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
TW200812962A (en) 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
WO2008008020A1 (en) * 2006-07-12 2008-01-17 Astrazeneca Ab 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
EP2076260B1 (en) 2006-09-15 2011-03-23 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013100027A1 (ja) 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
WO2013166015A1 (en) 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
KR101936851B1 (ko) * 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
WO2015002230A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
JP6501782B2 (ja) 2013-09-05 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしての二環式化合物
EP3077372B8 (en) 2013-12-05 2019-04-10 Lead Pharma Holding B.V. Ror gamma (rory) modulators
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015129853A1 (ja) 2014-02-27 2015-09-03 東レ株式会社 環状アミン誘導体及びその医薬用途
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
EA035063B1 (ru) 2014-04-14 2020-04-23 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве модуляторов ror гамма
KR20160146701A (ko) 2014-04-16 2016-12-21 그렌마크 파머수티칼스 에스. 아. Ror 감마 조절물질로서의 아릴 및 헤테로아릴 에테르 화합물
CR20170017A (es) 2014-07-01 2017-05-16 Takeda Pharmaceuticals Co Compuesto heterocíclico
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
CN107074852B (zh) 2014-10-14 2019-08-16 生命医药有限责任公司 ROR-γ的二氢吡咯并吡啶抑制剂
JP2017538676A (ja) 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US20180110774A1 (en) 2015-04-28 2018-04-26 Stc. Unm Compositions and methods for treatment of pulmonary hypertension
MY189194A (en) 2015-05-15 2022-01-31 Aurigene Discovery Tech Ltd Substituted tetrahydroquinolinone compounds as ror gamma modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
JP6778259B2 (ja) 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
SG11201804587QA (en) 2015-12-15 2018-06-28 Astrazeneca Ab Isoindole compounds

Also Published As

Publication number Publication date
DOP2018000148A (es) 2018-07-15
EA201891342A1 (ru) 2019-01-31
EA034514B1 (ru) 2020-02-14
CN109071516B (zh) 2021-08-31
MY196276A (en) 2023-03-24
IL259818B (en) 2021-05-31
CA3007893A1 (en) 2017-06-22
SV2018005713A (es) 2018-08-08
JP2018537485A (ja) 2018-12-20
WO2017102784A1 (en) 2017-06-22
ES2927631T3 (es) 2022-11-08
CN109071516A (zh) 2018-12-21
US10011566B2 (en) 2018-07-03
PH12018501237A1 (en) 2019-02-18
KR101947976B1 (ko) 2019-02-13
WO2017102784A9 (en) 2018-04-05
US11453644B1 (en) 2022-09-27
AU2016374294A1 (en) 2018-07-19
KR20180086269A (ko) 2018-07-30
US20190084934A1 (en) 2019-03-21
TW201738210A (zh) 2017-11-01
TN2018000188A1 (en) 2019-10-04
CL2018001573A1 (es) 2018-07-27
NI201800071A (es) 2018-10-18
EP3390396B1 (en) 2022-07-06
SG11201804587QA (en) 2018-06-28
US20170166527A1 (en) 2017-06-15
CO2018005983A2 (es) 2018-06-20
CR20180328A (es) 2018-08-09
US20200181084A1 (en) 2020-06-11
JP6448867B2 (ja) 2019-01-09
ZA201804618B (en) 2020-09-30
US10988445B2 (en) 2021-04-27
EP3390396A1 (en) 2018-10-24
MX2018007296A (es) 2019-01-10
IL259818A (en) 2018-07-31
AR107054A1 (es) 2018-03-14
US10526286B2 (en) 2020-01-07
BR112018011851A2 (pt) 2018-12-04
AU2016374294B2 (en) 2019-06-27
MX376029B (es) 2025-03-07
TWI728017B (zh) 2021-05-21

Similar Documents

Publication Publication Date Title
PE20181319A1 (es) Compuestos de isoindol
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
MX2019005306A (es) Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
PE20180258A1 (es) Inhibidores de bromodominio
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20151144A1 (es) Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
ECSP16082790A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
UA122869C2 (uk) Азолінові сполуки, заміщені конденсованою кільцевою системою
PE20150224A1 (es) Inhibidores del nampt
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA